RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

Table 1

Patient characteristics and KRAS mutation distribution.

Characteristics	N	Tissue; KRAS_Mt	Tissue; KRAS_Wt	Tissue; KRAS_NA	value	Plasma; KRAS_Mt	Plasma; KRAS_Wt	value
All patients	76	24	37	15		23	53
Age group					0.9712			0.9678
<65	46	15	22	9		14	32
≥65	30	9	15	6		9	21
Median (range)	62 (25–82)
Gender					0.9121			0.6654
Male	49	16	24	9		14	35
Female	27	8	13	6		9	18
Primary tumor site					0.4004			0.6555
Ascending colon	7	4	2	1		2	5
Transverse colon	4	0	2	2		1	3
Descending colon	10	2	6	2		2	8
Rectum, sigmoid colon	50	15	25	10		15	35
NA	5	3	2	0		3	2
Synchronous					0.2696			0.6005
Yes	24	10	10	4		9	15
No	50	14	27	10		14	37
NA	1	0	0	1		0	1
Liver metastases					0.3253			0.7328
Yes	32	8	17	7		11	21
No	43	16	20	7		12	31
NA	1	0	0	1		0	1
Perineural invasion					0.4695			0.4002
Yes	17	8	7	2		5	12
No	43	12	23	8		11	32
NA	16	4	7	5		7	9
Vascular tumor thrombus					0.7652			0.3025
Yes	17	7	8	2		5	12
No	41	12	21	8		10	31
NA	18	5	8	5		8	10
Number of metastatic sites					0.3196			0.3477
NA	1	0	0	1		0	1
0	5	0	5	0		0	5
1	30	9	14	7		8	22
2	25	8	12	5		8	17
>2	15	7	6	2		7	8
Histologic grade					0.5146			0.3066
NA	15	4	9	2		5	10
well differentiated	4	2	1	1		1	3
moderately differentiated	48	14	25	9		12	36
poorly differentiated	9	4	2	3		5	4